Acquisitions and Divestitures - Purchase Price Allocation for Six Months Ended December 2015 (Details) $ in Millions					6 Months Ended		12 Months Ended
		Dec. 15, 2015 USD ($)	Sep. 15, 2015 USD ($)	Aug. 28, 2015 USD ($) product	Dec. 31, 2015 USD ($) product		Dec. 31, 2017 USD ($) product	Dec. 31, 2016 USD ($) product		Jun. 27, 2015 USD ($) product
Assets acquired:
Goodwill					$ 5,152.7		$ 4,175.4	$ 4,049.4		$ 4,721.2
Liabilities assumed:
Business combination, number of products purchased | product							3	2		2
Entocort®
Business Acquisition [Line Items]
Purchase price paid		$ 380.2
Contingent consideration		0.0
Total purchase consideration		380.2
Assets acquired:
Cash and cash equivalents		0.0
Accounts receivable		0.0
Inventories		0.2
Goodwill		0.0
Indefinite-lived intangibles:
Total intangible assets		380.0
Total assets		380.2
Liabilities assumed:
Accounts payable		0.0
Accrued liabilities		0.0
Net deferred income tax liabilities		0.0
Total liabilities		0.0
Net assets acquired		380.2
Naturwohl
Business Acquisition [Line Items]
Purchase price paid			$ 150.4
Contingent consideration			0.0
Total purchase consideration			150.4
Assets acquired:
Cash and cash equivalents			4.6
Accounts receivable			3.3
Inventories			1.5
Goodwill			61.0
Indefinite-lived intangibles:
Total intangible assets			111.8
Total assets			182.2
Liabilities assumed:
Accounts payable			2.8
Accrued liabilities			1.6
Net deferred income tax liabilities			27.4
Total liabilities			31.8
Net assets acquired			150.4
ScarAway®
Business Acquisition [Line Items]
Purchase price paid				$ 26.7
Contingent consideration				0.0
Total purchase consideration				26.7
Assets acquired:
Cash and cash equivalents				0.0
Accounts receivable				0.0
Inventories				1.0
Goodwill				3.5
Indefinite-lived intangibles:
Total intangible assets				22.2
Total assets				26.7
Liabilities assumed:
Accounts payable				0.0
Accrued liabilities				0.0
Net deferred income tax liabilities				0.0
Total liabilities				0.0
Net assets acquired				$ 26.7
Business combination, number of products purchased | product				5
GSK Products
Business Acquisition [Line Items]
Purchase price paid				$ 223.6
Contingent consideration				0.0
Total purchase consideration				223.6
Assets acquired:
Cash and cash equivalents				0.0
Accounts receivable				0.0
Inventories				0.0
Goodwill				32.6
Indefinite-lived intangibles:
Total intangible assets				191.0
Total assets				223.6
Liabilities assumed:
Accounts payable				0.0
Accrued liabilities				0.0
Net deferred income tax liabilities				0.0
Total liabilities				0.0
Net assets acquired				223.6
All Other
Business Acquisition [Line Items]
Purchase price paid					15.3	[1]		$ 17.1	[2]
Contingent consideration					13.9	[1]		26.2	[2]
Total purchase consideration					29.2	[1]		43.3	[2]
Assets acquired:
Cash and cash equivalents					0.0	[1]		3.8	[2]
Accounts receivable					0.0	[1]		4.9	[2]
Inventories					0.0	[1]		7.1	[2]
Goodwill					0.0	[1]		0.0	[2]
Indefinite-lived intangibles:
Total intangible assets					29.2	[1]		32.9	[2]
Total assets					29.2	[1]		50.0	[2]
Liabilities assumed:
Accounts payable					0.0	[1]		2.8	[2]
Accrued liabilities					0.0	[1]		0.1	[2]
Net deferred income tax liabilities					0.0	[1]		0.5	[2]
Total liabilities					0.0	[1]		6.7	[2]
Net assets acquired					$ 29.2	[1]		$ 43.3	[2]
Business combination, number of products purchased | product					8			4
Distribution and license agreements, supply agreements | Entocort®
Definite-lived intangibles:
Definite-lived intangibles		0.0
Distribution and license agreements, supply agreements | Naturwohl
Definite-lived intangibles:
Definite-lived intangibles			21.4
Distribution and license agreements, supply agreements | ScarAway®
Definite-lived intangibles:
Definite-lived intangibles				0.0
Distribution and license agreements, supply agreements | GSK Products
Definite-lived intangibles:
Definite-lived intangibles				0.0
Distribution and license agreements, supply agreements | All Other
Definite-lived intangibles:
Definite-lived intangibles					$ 0.0	[1]		$ 1.8	[2]
Developed product technology, formulations, and product rights | Entocort®
Definite-lived intangibles:
Definite-lived intangibles		380.0
Developed product technology, formulations, and product rights | Naturwohl
Definite-lived intangibles:
Definite-lived intangibles			0.0
Developed product technology, formulations, and product rights | ScarAway®
Definite-lived intangibles:
Definite-lived intangibles				0.5
Developed product technology, formulations, and product rights | GSK Products
Definite-lived intangibles:
Definite-lived intangibles				0.0
Developed product technology, formulations, and product rights | All Other
Definite-lived intangibles:
Definite-lived intangibles					0.0	[1]		18.0	[2]
Customer relationships and distribution networks | Entocort®
Definite-lived intangibles:
Definite-lived intangibles		0.0
Customer relationships and distribution networks | Naturwohl
Definite-lived intangibles:
Definite-lived intangibles			25.9
Customer relationships and distribution networks | ScarAway®
Definite-lived intangibles:
Definite-lived intangibles				9.8
Customer relationships and distribution networks | GSK Products
Definite-lived intangibles:
Definite-lived intangibles				61.5
Customer relationships and distribution networks | All Other
Definite-lived intangibles:
Definite-lived intangibles					0.0	[1]		8.2	[2]
Trademarks, trade names, and brands | Entocort®
Definite-lived intangibles:
Definite-lived intangibles		0.0
Trademarks, trade names, and brands | Naturwohl
Definite-lived intangibles:
Definite-lived intangibles			64.2
Trademarks, trade names, and brands | ScarAway®
Definite-lived intangibles:
Definite-lived intangibles				11.4
Trademarks, trade names, and brands | GSK Products
Definite-lived intangibles:
Definite-lived intangibles				129.5
Trademarks, trade names, and brands | All Other
Definite-lived intangibles:
Definite-lived intangibles	[1]				0.0
Non-compete agreements | Entocort®
Definite-lived intangibles:
Definite-lived intangibles		0.0
Non-compete agreements | Naturwohl
Definite-lived intangibles:
Definite-lived intangibles			0.3
Non-compete agreements | ScarAway®
Definite-lived intangibles:
Definite-lived intangibles				0.5
Non-compete agreements | GSK Products
Definite-lived intangibles:
Definite-lived intangibles				0.0
Non-compete agreements | All Other
Definite-lived intangibles:
Definite-lived intangibles					0.0	[1]		0.0	[2]
In-process research and development | Entocort®
Indefinite-lived intangibles:
Indefinite-lived intangibles		$ 0.0
In-process research and development | Naturwohl
Indefinite-lived intangibles:
Indefinite-lived intangibles			$ 0.0
In-process research and development | ScarAway®
Indefinite-lived intangibles:
Indefinite-lived intangibles				0.0
In-process research and development | GSK Products
Indefinite-lived intangibles:
Indefinite-lived intangibles				$ 0.0
In-process research and development | All Other
Indefinite-lived intangibles:
Indefinite-lived intangibles					$ 29.2	[1]		$ 4.9	[2]

[1] Consists of eight product development acquisitions in our CHCA, CHCI and RX segments.

[2] Consists of four product acquisitions in our CHCA, CHCI and RX segments.